Home › Companies › NEKTAR THERAPEUTICS › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NEKTAR THERAPEUTICS’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2024: 6 items on NEKTAR THERAPEUTICS’s Form 8-K, filed June 6, 2024: 3 elected · 3 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 9.8%, as of September 30, 2026)
Explore NEKTAR THERAPEUTICS in the interactive database Compare manager voting policies
These tallies are NEKTAR THERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeff Ajer | 89,572,592 | 5,310,752 | 5,112,487 | -- | 46,683,689 | 94% | Elected | — |
| Elect Director: Robert B. Chess | 87,385,092 | 7,518,984 | 5,091,755 | -- | 46,683,689 | 92% | Elected | — |
| Elect Director: Roy A. Whitfield | 85,885,290 | 8,993,582 | 5,116,959 | -- | 46,683,689 | 91% | Elected | — |
| 2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares | 86,500,506 | 7,507,037 | 5,988,288 | -- | 46,683,689 | 92% | Approved | — |
| 3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 139,098,119 | 1,556,508 | 6,024,893 | -- | 0 | 99% | Approved | — |
| 4. Proposal to approve the non-binding advisory resolution regarding our executive compensation | 87,037,178 | 6,730,748 | 6,227,905 | -- | 46,683,689 | 93% | Approved | — |
Source: NEKTAR THERAPEUTICS, Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
124 asset managers disclosed a vote on at least one NEKTAR THERAPEUTICS item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jeff Ajer
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Jeff Ajer”): 89,572,592 for, 5,310,752 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 23,712,753 for, 219,719 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert B. Chess
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Robert B. Chess”): 87,385,092 for, 7,518,984 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 23,582,241 for, 350,231 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 0 | 50,263 | 0 | 0 | Against |
| Jackson National | 0 | 39,748 | 0 | 0 | Against |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 15,605 | 0 | 0 | Against |
| Allianz | 0 | 14,311 | 0 | 0 | Against |
| John Hancock | 0 | 10,585 | 0 | 0 | Against |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Roy A. Whitfield
NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Roy A. Whitfield”): 85,885,290 for, 8,993,582 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 22,931,243 for, 1,001,229 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 0 | 525,125 | 0 | 0 | Against |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 256,385 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,000,000 shares.
NEKTAR THERAPEUTICS’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares”): 86,500,506 for, 7,507,037 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares was approved with the following votes.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 23,742,503 for, 220,419 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 219,719 | 0 | 0 | Against |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 29,430 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
| MIDDLETON & CO INC/MA | 0 | 700 | 0 | 0 | Against |
| GRIMES & COMPANY, INC. | 320 | 0 | 0 | 0 | For |
Combines 9 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).
NEKTAR THERAPEUTICS’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 87,037,178 for, 6,730,748 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 219,719 | 0 | 0 | 0 | For |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Fund voting reports, all 20 managers: 23,932,472 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 18,400,000 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 6,926,347 | 0 | 0 | 0 | For |
| Monaco Asset Management SAM | 0 | 0 | 5,030,874 | 0 | Abstain |
| Citadel | 4,484,623 | 0 | 0 | 0 | For |
| BlackRock | 4,047,579 | 0 | 0 | 0 | For |
| Two Sigma | 3,537,152 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 2,962,225 | 0 | 0 | 0 | For |
| Renaissance | 2,952,710 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 2,819,078 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 2,817,753 | 0 | 0 | 0 | For |
| DE Shaw | 2,328,908 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 2,073,585 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,053,085 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,233,051 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 1,099,131 | 0 | 0 | Against |
| UBS | 948,930 | 0 | 0 | 0 | For |
| State Street | 690,226 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 575,867 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Dimensional | 409,525 | 0 | 0 | 0 | For |
| Northern Trust | 333,437 | 0 | 0 | 0 | For |
| Woodline Partners LP | 270,209 | 0 | 0 | 0 | For |
| AQR | 266,579 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 256,385 | 0 | 0 | 0 | For |
Institutional-manager reports, all 107 managers: 63,297,723 for, 1,126,881 against, 5,030,874 abstained, 10,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 97.6% for (June 8, 2023 meeting) ▲ 1.3 pts
Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
NEKTAR THERAPEUTICS’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 139,098,119 for, 1,556,508 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with the following votes.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 23,932,472 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,980,194 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 6,305,736 | 0 | 0 | 0 | For |
| Fidelity | 1,872,388 | 0 | 0 | 0 | For |
| Charles Schwab | 1,129,130 | 0 | 0 | 0 | For |
| BlackRock | 982,904 | 0 | 0 | 0 | For |
| Invesco | 525,125 | 0 | 0 | 0 | For |
| Nationwide | 277,405 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 256,385 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 219,719 | 0 | 0 | 0 | For |
| GuideStone | 87,519 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 50,456 | 0 | 0 | 0 | For |
| Dimensional | 50,263 | 0 | 0 | 0 | For |
| Jackson National | 39,748 | 0 | 0 | 0 | For |
| Russell Investments | 32,901 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 29,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 28,298 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 24,800 | 0 | 0 | 0 | For |
| Lincoln Financial | 15,605 | 0 | 0 | 0 | For |
| Allianz | 14,311 | 0 | 0 | 0 | For |
| John Hancock | 10,585 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 183,624,620 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.52% |
| 2 | PRIMECAP Odyssey Funds | 3.43% |
| 3 | Fidelity | 1.02% |
| 4 | Charles Schwab | 0.61% |
| 5 | BlackRock | 0.54% |
| 6 | Invesco | 0.29% |
| 7 | Nationwide | 0.15% |
| 8 | Delaware/Macquarie | 0.14% |
| 9 | Columbia Threadneedle | 0.12% |
| 10 | GuideStone | 0.05% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 10.02% |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3.77% |
| 3 | Monaco Asset Management SAM | 2.74% |
| 4 | Citadel | 2.44% |
| 5 | BlackRock | 2.20% |
| 6 | Two Sigma | 1.93% |
| 7 | Ensign Peak Advisors, Inc | 1.61% |
| 8 | Renaissance | 1.61% |
| 9 | Nantahala Capital Management, LLC | 1.54% |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 1.53% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| TCG Crossover GP II, LLC | 20,046,350 | 10.92% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Deep Track Capital, LP | 18,400,000 | 10.02% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| The Vanguard Group | 12,042,873 | 6.56% | Schedule 13G, filed February 13, 2024 |
| Renaissance Technologies | 4,620,681 | 2.52% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 2,984,545 | 1.63% | Form 13F, quarter ended March 31, 2024 |
| Howard W. Robin | 2,839,358 | 1.55% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| D.E. Shaw | 2,548,990 | 1.39% | Form 13F, quarter ended March 31, 2024 |
| Two Sigma | 2,081,940 | 1.13% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,053,085 | 1.12% | Form 13F, quarter ended March 31, 2024 |
| Jonathan Zalevsky, Ph.D. | 1,279,828 | 0.70% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
Percentages above are of 183,624,620 shares outstanding, as reported by NEKTAR THERAPEUTICS on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At NEKTAR THERAPEUTICS's shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 124 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 392 separate fund positions. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — NEKTAR THERAPEUTICS's filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NEKTAR THERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEKTAR THERAPEUTICS’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
NEKTAR THERAPEUTICS proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “NEKTAR THERAPEUTICS (NKTR) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nektar-therapeutics/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.